CD274 and malignant peripheral nerve sheath tumor: Case studies have reported deep and/or or complete responses to pembrolizumab, a PD-1 receptor inhibitor, in the treatment of PD-L1 positive relapsed/refractory MPNST [118,119,120], and several clinical trials of ICB in MPNST are currently underway.